Cencora, Inc. Files 8-K Report
Ticker: COR · Form: 8-K · Filed: Sep 5, 2024 · CIK: 1140859
| Field | Detail |
|---|---|
| Company | Cencora, INC. (COR) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $13.60, $13, $13.55, $13.65 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
TL;DR
Cencora filed a routine 8-K on Sept 5th, no major news.
AI Summary
On September 5, 2024, Cencora, Inc. (formerly AmerisourceBergen Corp) filed an 8-K report. The filing indicates no specific material events or disclosures beyond routine reporting requirements for the date.
Why It Matters
This filing serves as a standard notification to the SEC and investors about significant corporate events, though this specific report does not detail any major changes.
Risk Assessment
Risk Level: low — The filing is a standard 8-K current report with no disclosed material events, indicating no immediate new risks.
Key Players & Entities
- Cencora, Inc. (company) — Registrant
- AmerisourceBergen Corp (company) — Former company name
- September 5, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Cencora, Inc.?
The primary purpose is to report significant corporate events or information as required by the SEC, serving as a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What was Cencora, Inc.'s former name?
Cencora, Inc.'s former name was AmerisourceBergen Corp.
On what date was this 8-K filing reported?
The filing was reported as of September 5, 2024.
What is Cencora, Inc.'s principal executive office address?
Cencora, Inc.'s principal executive offices are located at 1 West First Avenue, Conshohocken, PA 19428-1800.
What is Cencora, Inc.'s IRS Employer Identification Number?
Cencora, Inc.'s IRS Employer Identification Number is 23-3079390.
Filing Stats: 917 words · 4 min read · ~3 pages · Grade level 12.4 · Accepted 2024-09-05 07:30:43
Key Financial Figures
- $13.60 — 4 is now expected to be in the range of $13.60 to $13.70, up from the previous range o
- $13 — xpected to be in the range of $13.60 to $13.70, up from the previous range of $13.5
- $13.55 — o $13.70, up from the previous range of $13.55 to $13.65. This updated guidance reflec
- $13.65 — up from the previous range of $13.55 to $13.65. This updated guidance reflects the Com
Filing Documents
- tm2423361d1_8k.htm (8-K) — 29KB
- 0001104659-24-097135.txt ( ) — 198KB
- cor-20240905.xsd (EX-101.SCH) — 3KB
- cor-20240905_lab.xml (EX-101.LAB) — 33KB
- cor-20240905_pre.xml (EX-101.PRE) — 22KB
- tm2423361d1_8k_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. Executives of Cencora, Inc. (the "Company") will be presenting at the Morgan Stanley Healthcare Conference today at 4:05 p.m. ET, as well as at the Wells Fargo Healthcare Conference on September 6, 2024 and the Baird Healthcare Conference on September 11, 2024. During these events the Company's executives will provide updates regarding certain performance expectations and recent business developments, including: Adjusted diluted EPS for fiscal year 2024 is now expected to be in the range of $13.60 to $13.70, up from the previous range of $13.55 to $13.65. This updated guidance reflects the Company's continued strong results. Full fiscal year 2025 adjusted operating income and adjusted diluted EPS growth are expected to be at the bottom end of the Company's long-term growth target ranges of 5% to 8% and 8% to 12%, respectively, primarily due to: o The expected year-over-year headwind from COVID products, including: commercial COVID vaccines; and the previously disclosed headwind from exclusive COVID therapy contribution in the fiscal year 2024 first quarter; and o Additionally, and to a lesser extent, the Company is factoring in the potential June 2025 loss of an oncology customer following its recently announced pending acquisition. The Company recently extended its pharmaceutical supply agreement with Evernorth Health Services (formerly Express Scripts) for an additional three years through September 2029. Live webcasts and subsequent replays of the presentations can be accessed from the Company's Investor Relations website at investor.cencora.com. Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Words such as "aim," "anticipate," "believe," "can," "con
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CENCORA, INC. September 5, 2024 By: /s/ James F. Cleary Name: James F. Cleary Title: Executive Vice President and Chief Financial Officer